Regeneron Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise-July 2024-www.financetom.com

Regeneron Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Regeneron Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise

Apr 29, 2026 4:12 AM

06:58 AM EDT, 04/29/2026 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) reported Q1 adjusted earnings Wednesday of $9.47 per share, up from $8.22 a year earlier.

Analysts surveyed by FactSet expected $8.91.

Revenue for the quarter ended March 31 was $3.61 billion, up from $3.03 billion a year earlier.

Analysts polled by FactSet expected $3.48 billion.

The company also said it repurchased $803 million of shares during the quarter, and its board authorized a new $3 billion share repurchase program in April.

The board also declared a cash dividend of $0.94 per share, payable June 4 to shareholders of record as of May 20.

Shares of the company were up 1.8% in Wednesday premarket activity.

Previous page： DoubleDown Confirms Receipt of a Non-Binding Expression of Interest from Controlling Shareholder, DoubleU Games, to Acquire all Outstanding Common Shares and ADSs Next page： Vaccine Star Shingrix Lifts GSK, But Weak Segments Raise Eyebrows

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

DoubleDown Confirms Receipt of a Non-Binding Expression of Interest from Controlling Shareholder, DoubleU Games, to Acquire all Outstanding Common Shares and ADSs

Apr 29, 2026

SEOUL, South Korea, April 29, 2026 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. ( DDI ) (“DoubleDown” or the “Company”) today confirmed receipt of a non-binding expression of interest from DoubleU Games Co., Ltd. (“DUG”), the Company’s controlling shareholder holding approximately 67.1% of the Company’s outstanding common shares, to acquire all of the outstanding common shares (including American Depositary Shares,...

Vaccine Star Shingrix Lifts GSK, But Weak Segments Raise Eyebrows

Apr 29, 2026

British pharmaceutical company GSK Plc ( GSK ) on Wednesday reported first-quarter core earnings of $1.25 per share (46.5 pence), beating the consensus estimate of $1.17. Earnings rose 4%, or 9% at constant currency. Quarterly sales totaled $10.22 billion (7.63 billion pounds), up 2% year over year, or 5% at constant currency, and ahead of analyst estimates of $10.19 billion....

BNCCORP To Be Acquired By OppFi in Transformative Customer-Focused Transaction

Apr 29, 2026

BISMARCK, N.D., April 29, 2026 /PRNewswire/ -- BNCCORP, INC. ( BNCC ) (BNCC) and its wholly owned subsidiary, BNC National Bank (BNC) announced today it has signed a definitive agreement to be acquired by OppFi Inc. ( OPFI ) , a tech-enabled digital finance platform, in a cash and stock transaction valued at approximately $130 million. The transaction brings together...

Regeneron Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise

Apr 29, 2026

06:58 AM EDT, 04/29/2026 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) reported Q1 adjusted earnings Wednesday of $9.47 per share, up from $8.22 a year earlier. Analysts surveyed by FactSet expected $8.91. Revenue for the quarter ended March 31 was $3.61 billion, up from $3.03 billion a year earlier. Analysts polled by FactSet expected $3.48 billion. The company also...